pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 25 Non-oncology: 17
Oncology: 8
Under Consideration for Negotiation 26 Non-oncology: 14
Oncology: 12
Completed Negotiations 677 With Letter of Intent: 580
Without agreement: 97
Negotiations That Were Not Pursued 101

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Vyalev AbbVie Corporation For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson's disease.
SIR-Spheres Y-90 resin microspheres Sirtex Medical Hepatocellular carcinoma
TheraSphere Y-90 Glass Micropheres Boston Scientific Corporation Hepatocellular carcinoma
Yescarta Gilead Sciences Canada Inc. The treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy.
Zoryve Arcutis Biotherapeutics, Inc. Plaque psoriasis
Rukobia ViiV Healthcare For use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to co

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Imfinzi and Imjudo ASTRAZENECA CANADA INC Imjudo (tremelimumab for injection) in combination with durvalumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who require systemic therapy.
Imfinzi AstraZeneca Canada Inc. In combination with gemcitabine-based chemotherapy for the treatment of patients with locally advanced or metastatic biliary tract cancer (BTC)
Jamteki Jamp Pharma Corporation Multiple indications

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Ultomiris Alexion Pharma GMBH AChR antibody-positive generalized Myasthenia Gravis